| The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts YC Cohen, B Djulbegovic, O Shamai-Lubovitz, B Mozes Archives of internal medicine 160 (11), 1630-1638, 2000 | 543 | 2000 |
| Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma G Ledergor, A Weiner, M Zada, SY Wang, YC Cohen, ME Gatt, N Snir, ... Nature medicine 24 (12), 1867-1876, 2018 | 218 | 2018 |
| Comparison of factors associated with 30-day mortality after coronary artery bypass grafting in patients with versus without diabetes mellitus Y Cohen, I Raz, G Merin, B Mozes The American journal of cardiology 81 (1), 7-11, 1998 | 153 | 1998 |
| Detection bias due to the effect of finasteride on prostate volume: a modeling approach for analysis of the Prostate Cancer Prevention Trial YC Cohen, KS Liu, NL Heyden, AD Carides, KM Anderson, AG Daifotis, ... Journal of the National Cancer Institute 99 (18), 1366-1374, 2007 | 147 | 2007 |
| Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing YC Cohen, M Zada, SY Wang, C Bornstein, E David, A Moshe, B Li, ... Nature medicine 27 (3), 491-503, 2021 | 145 | 2021 |
| Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma C Perry, E Luttwak, R Balaban, G Shefer, MM Morales, A Aharon, Y Tabib, ... Blood advances 5 (16), 3053-3061, 2021 | 141 | 2021 |
| Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma J San-Miguel, B Dhakal, K Yong, A Spencer, S Anguille, MV Mateos, ... New England Journal of Medicine, 2023 | 129 | 2023 |
| Factors affecting mortality following myeloablative cord blood transplantation in adults: a pooled analysis of three international registries YC Cohen, A Scaradavou, CE Stevens, P Rubinstein, E Gluckman, ... Bone marrow transplantation 46 (1), 70-76, 2011 | 103 | 2011 |
| Humoral response rate and predictors of response to BNT162b2 mRNA COVID19 vaccine in patients with multiple myeloma I Avivi, R Balaban, T Shragai, G Sheffer, M Morales, A Aharon, ... British journal of haematology 195 (2), 186-193, 2021 | 78 | 2021 |
| Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents AD Cohen, MV Mateos, YC Cohen, P Rodriguez-Otero, B Paiva, ... Blood, The Journal of the American Society of Hematology 141 (3), 219-230, 2023 | 70 | 2023 |
| Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS) CO Landgren, A Chari, YC Cohen, A Spencer, P Voorhees, JA Estell, ... Leukemia 34 (7), 1840-1852, 2020 | 69 | 2020 |
| Extensive venous and arterial thrombosis associated with an inhibitor to activated protein C A Zivelin, S Gitel, JH Griffin, X Xu, JA Fernandez, U Martinowitz, Y Cohen, ... Blood, The Journal of the American Society of Hematology 94 (3), 895-901, 1999 | 60 | 1999 |
| A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE) TF Cloughesy, A Brenner, JF De Groot, NA Butowski, L Zach, JL Campian, ... Neuro-oncology 22 (5), 705-717, 2020 | 59 | 2020 |
| Factors affecting change in quality of life after prostatectomy for benign prostatic hypertrophy: the impact of surgical techniques B Mozes, YC Cohen, L Olmer, E Shabtai The Journal of urology 155 (1), 191-196, 1996 | 57 | 1996 |
| Cohort-controlled comparison of umbilical cord blood transplantation using carlecortemcel-L, a single progenitor–enriched cord blood, to double cord blood unit transplantation PJ Stiff, P Montesinos, T Peled, E Landau, NR Goudsmid, J Mandel, ... Biology of Blood and Marrow Transplantation 24 (7), 1463-1470, 2018 | 49 | 2018 |
| Correlation between BNT162b2 mRNA Covid-19 vaccine-associated hypermetabolic lymphadenopathy and humoral immunity in patients with hematologic malignancy D Cohen, S Hazut Krauthammer, YC Cohen, C Perry, I Avivi, Y Herishanu, ... European Journal of Nuclear Medicine and Molecular Imaging 48 (11), 3540-3549, 2021 | 42 | 2021 |
| Daratumumab monotherapy for patients with intermediate or high-risk smoldering multiple myeloma (SMM): Centaurus, a randomized, open-label, multicenter phase 2 study CC Hofmeister, A Chari, Y Cohen, A Spencer, PM Voorhees, J Estell, ... Blood 130, 510, 2017 | 39 | 2017 |
| Efficacy and safety of salvage therapy using Carfilzomib for relapsed or refractory multiple myeloma patients: a multicentre retrospective observational study E Muchtar, ME Gatt, O Rouvio, C Ganzel, E Chubar, C Suriu, T Tadmor, ... British Journal of Haematology 172 (1), 89-96, 2016 | 38 | 2016 |
| Hematogenous extramedullary relapse in multiple myeloma‐a multicenter retrospective study in 127 patients I Avivi, YC Cohen, A Suska, T Shragai, G Mikala, L Garderet, GM Seny, ... American Journal of Hematology 94 (10), 1132-1140, 2019 | 37 | 2019 |
| Safety and efficacy of VB-111, an anticancer gene therapy, in patients with recurrent glioblastoma: results of a phase I/II study AJ Brenner, KB Peters, J Vredenburgh, F Bokstein, DT Blumenthal, ... Neuro-oncology 22 (5), 694-704, 2020 | 34 | 2020 |
